Prima BioMed Ltd
Prima BioMed Ltd is listed today as Immutep Ltd: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2018 | $5 M | No. 2 | $2 to $10 million | options | SEC | |
| Jun 2017 | $5 M | No. 1 | $2 to $10 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Prima BioMed Ltd chose not to state its revenue in its newest notice of a funding round (Dec 2018).
SEC Form D · Dec 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2018
That is all the official record says: Prima BioMed Ltd has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products#
- etilagimod alpha
From the company page of Immutep Ltd.
Services#
No services of Prima BioMed Ltd are on record.
Investors#
No investor of Prima BioMed Ltd is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.
Largest shareholders today
Institutions holding Immutep Ltd shares, as of Sep 30, 2026.
- BlackRock, Inc.$0 M—
- HSBC Holdings PLC$0 M—
- Rhumbline Advisers$0 M—
- UBS Group AG$0 M—
- US Bancorp \de\$0 M—
- Tower Research Capital LLC (TRC)$0 M—
- Simplex Trading, LLC$0 M—
- SBI Securities Co., Ltd.$0 M—
- Morgan Stanley$0 M—
- Northwestern Mutual Wealth Management Co$0 M—
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Deanne John Miller | Executive officer | Dec 2018 |
| Frederic John Triebel | Executive officer | Dec 2018 |
| Marc Voigt | Executive officer | Dec 2018 |
| Deanne Miller | Executive officer | Jul 2017 |
| Frederic Triebel | Executive officer | Jul 2017 |
| Grant Chamberlain | Director | Dec 2018 |
| Marc Voigt | Director | Dec 2018 |
| Pete John Meyers | Director | Dec 2018 |
| Russell John Howard | Director | Dec 2018 |
| Albert Wong | Director | Jul 2017 |
| Deanne Miller | Director | Jul 2017 |
| Frederic Triebel | Director | Jul 2017 |
| Lucy Turnbull | Director | Jul 2017 |
| Peter Meyers | Director | Jul 2017 |
| Russell Howard | Director | Jul 2017 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.